Skip to main content

ISOP ACoP 2025 Annual Conference Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

E
T-112
Early sampling improves voriconazole target attainment in pediatric patients dosed with model-informed precision dosing tools: a simulation study

Favorite
S-001
Easy model creation using nlmixr2shiny and nlmixr2lib

Favorite
T-051
Efficient Generation of Plausible Virtual Populations Using Machine Learning Surrogate Classification Models

Favorite
T-096
Enabling Earlier Predictions of Hepatotoxic Risk with Quantitative Structure-Activity Relationship-Machine Learning (QSAR-ML) and Quantitative Systems Toxicology (QST) Models

Favorite
M-026
Enhancing Clinical Trial Simulations with Advanced Computational Techniques and Scalable Cloud Solutions

Favorite
M-025
Enhancing Model Interoperability and Workflow Integration in Clinical Trial Simulations

Favorite
S-018
Evaluating antibody drug conjugate (ADC) combinations using the platform Quantitative Systems Pharmacology (QSP) model

Favorite
M-046
Evaluating the feasibility of virtual controls in organ impairment studies using modeling and simulation

Favorite
M-098
Evaluating the impact of pharmacogenomic variants on aromatase inhibitor-induced bone toxicity using a quantitative systems pharmacology model of bone remodeling

Favorite
M-098
Evaluating the impact of pharmacogenomic variants on aromatase inhibitor-induced bone toxicity using a quantitative systems pharmacology model of bone remodeling

Favorite
S-069
Evaluation and Mitigation of Time-Dependent Confounding Effects in Conventional Exposure-Response Analyses for Small-Molecule Oncology Drugs

Favorite
M-038
Evaluation of Azithromycin Disposition in Pregnant Women Undergoing Cesarean Delivery – A Population-Based PBPK Modeling Approach

Favorite
S-026
Evaluation of Fluctuating Drug Concentration and Pharmacokinetic Effects on Time-to-event Endpoint Using Proportional Hazard Cox Regression in NONMEM

Favorite
T-012
Evaluation of Parallel Tempering for Efficient Generation of Virtual Populations

Favorite
M-053
Exploratory population pharmacokinetic analysis of vixarelimab using a two-target quasi-steady-state TMDD model in healthy volunteers and patients with pruritic conditions

Favorite
S-032
Exploring Python to Prepare CDISC-Compliant Analysis Datasets for Pharmacometric Analyses

Favorite
S-075
Exposure-Overall Survival Analysis for Quizartinib in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukemia

Favorite
M-073
Exposure-Response Analyses for Monthly Buprenorphine Extended-Release (BUP-XR) in Patients with Opioid Use Disorder and Frequent Fentanyl Use

Favorite
S-048
Exposure-Response Analyses of Dato-DXd in patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer

Favorite
T-087
Exposure-Response Analysis of Bleeding Events Following Weekly SC Flat Dose Marstacimab Administration in Hemophilia Participants Using Regression Modeling and Repeated-Time-To-Event (RTTE) Analyses

Favorite
T-100
Exposure-Response Analysis of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Patients with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Favorite
M-008
Exposure-Response Analysis of Efficacy and Safety for Nivolumab + Relatlimab Fixed-dose Combination (FDC) to Support Dose Justification in Patients with Unresectable or Metastatic Melanoma

Favorite
T-083
Exposure-Response Analysis of Guselkumab in Induction Studies in Adults with Moderately to Severely Active Ulcerative Colitis in the QUASAR Program

Favorite
T-083
Exposure-Response Analysis of Guselkumab in Induction Studies in Adults with Moderately to Severely Active Ulcerative Colitis in the QUASAR Program

Favorite
M-052
Exposure-Response Analysis of Guselkumab in Participants with Moderate to Severe Crohn’s Disease

Favorite
T-062
Exposure-Response Analysis of Guselkumab in the Maintenance Phase in Adults with Moderately to Severely Active Ulcerative Colitis

Favorite
M-031
Exposure-Response Analysis of Seladelpar in Patients With Primary Biliary Cholangitis

Favorite
S-004
Exposure-Response Analysis of Ziftomenib in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Favorite
S-076
Exposure-Response Characterization of the Safety Profile for a Novel KAT6 Inhibitor, PF-07248144, For Use In Dose Optimization During a Phase 1 First-in-Patient Study

Favorite
T-078
Exposure-Response Modeling of Efficacy and Safety Endpoints of Sarilumab in Pediatric Patients with Polyarticular-Course Juvenile Arthritis

Favorite
M-111
Exposure-Response Relationship Between Litifilimab and Clinical Outcomes in Systemic Lupus Erythematosus Populations

Favorite